Shanghai Auzone
- Biotech or pharma, therapeutic R&D
- The first and world only edaravone oral tablet. Potential clinical benefits on the approved indications (AIS and ALS) and new indications (AD, Autism, acute mountain diseases)
- ALS: NDA for ALS treatment filed with US FDA in 2024 and expected to be approved by Oct 2025.
- AIS: A phase 3 study for acute ischemic stroke (AIS) completed in 2024 in China and the commercial rights licensed out to Huadong Pharma, China. IND for global phase 3 for AIS was approved by US FDA in Apr 2025.
- Autism: a phase 2 trial is ongoing in China and will be completed in early 2026
- AD: a phase 2 will be conducted in Australia and China soon
Address
SuzhouJiangsu
China
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}